Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
09 Julio 2024 - 6:13AM
Tokyo, Japan and Cambridge, UK, 9 July 2024 -
Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings
results and present operational highlights for the 6 months ended
30 June 2024 on Friday, 9 August 2024.
The Company will host a live webinar
presentation with Chris Cargill, President and CEO, Hironoshin
Nomura, CFO, Matt Barnes, EVP, President of Nxera Pharma UK, Head
of R&D and Satoshi Tanaka, EVP, President of Nxera Pharma Japan
at 4:30 pm JST (8:30 am BST) on Friday, 9 August 2024.
The webinar is open to all existing and
potential investors as well as sell-/buy-side analysts and will
consist of a presentation followed by a Q&A session. Please
click here to pre-register, which will provide a link to access the
webinar.
Presentation slides will be made available by 4
pm JST (8 am BST) on 9 August 2024 through the investor section of
the Company’s Home Page here.
– ENDS –
About Nxera
Pharma
Nxera Pharma (formerly Sosei Heptares) is a
technology powered biopharma company, in pursuit of new specialty
medicines to improve the lives of patients with unmet needs in
Japan and globally.
In addition to several products being
commercialized in Japan, we are advancing an extensive pipeline of
over 30 active programs from discovery through to late clinical
stage internally and in partnership with leading pharma and biotech
companies. This pipeline is focused on addressing major unmet needs
in some of the fastest-growing areas of medicine across neurology,
GI and immunology, metabolic disorders and rare diseases, and
leverages the power of our unique and industry leading
GPCR-targeted structure-based drug discovery NxWave™ platform to
provide a sustainable source of best- or first-in-class
candidates.
Nxera employs over 350 talented people at key
locations in Tokyo and Osaka (Japan), London and Cambridge (UK),
Basel (Switzerland) and Seoul (South Korea) and is listed on the
Tokyo Stock Exchange (ticker: 4565).
For more information, please visit www.nxera.lifeLinkedIn:
@NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
Enquiries:
Nxera Pharma Kentaro Tahara, VP Investor
Relations and Corporate Strategy Shinichiro Nishishita, VP Investor
Relations, Head of Regulatory Disclosures Maya Bennison,
Communications Manager +81 (0)3 5210 3399 | +44 (0)1223 949390 |
IR@Nxera.life
MEDiSTRAVA (for International Media) Mark
Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 |
Nxera@medistrava.com
Forward-looking statements
This press release contains forward-looking
statements, including statements about the discovery, development,
and commercialization of products. Various risks may cause Nxera
Pharma Group’s actual results to differ materially from those
expressed or implied by the forward looking statements, including:
adverse results in clinical development programs; failure to obtain
patent protection for inventions; commercial limitations imposed by
patents owned or controlled by third parties; dependence upon
strategic alliance partners to develop and commercialize products
and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from
development efforts; the requirement
for substantial funding to conduct research and development and
to expand commercialization activities; and product initiatives by
competitors. As a result of these factors, prospective investors
are cautioned not to rely on any forward-looking statements. We
disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.